Clinigene Launches a Best-in-class Biomarker Assay for Measuring "ABCA1 Specific Cholesterol Efflux" - News and Weather For The Quad Cities -

Clinigene Launches a Best-in-class Biomarker Assay for Measuring "ABCA1 Specific Cholesterol Efflux"

Information contained on this page is provided by an independent third-party content provider. WorldNow and this Station make no warranties or representations in connection therewith. If you have any questions or comments about this page please contact pressreleases@worldnow.com.

SOURCE Clinigene International Limited

BANGALORE, India, June 9, 2014 /PRNewswire/ --

Clinigene International Ltd, a subsidiary of Syngene International  Ltd, India's leading Contract Research Services provider, today announced that it has launched a cholesterol efflux assay to support global aspirants developing cholesterol lowering drugs. This biomarker assay is a cell based assay for assessing the ATP-binding cassette A1 (ABCA1) specific cholesterol efflux capacity in human serum samples.

     (Logo: http://photos.prnewswire.com/prnh/20140609/690595 )

Speaking on this occasion, Dr. Aparna Kasinath, Head of the Bioanalytical Laboratory, said "Atherosclerotic cardiovascular diseases are the major causes of morbidity and mortality worldwide. Globally, an enormous amount of research effort has been invested into improving the current understanding of molecular pathways that control HDL-C. Biopharma companies are exploring new therapeutic approaches that impact HDL-C. These novel therapies require a better understanding of the functional properties of the HDL particle. Cholesterol efflux capacity through the ABCA1 transporter is so far the best understood functional property of HDL with substantial supportive clinical evidence". "While there are a limited number of alternative Cholesterol Efflux assays in the market, Clinigene's assay is superior in reproducibility and throughput, and therefore  better suited for regulated analysis of samples from large scale clinical trials" Dr Kasinath continued.

"Clinigene operates a CAP-accredited central lab and GLP-compliant Bioanalytical laboratory for small and large molecule therapeutics and has deep expertise in GLP validation of cell based assays and regulated analysis of samples from large scale, multi-site clinical trials. In developing this assay we collaborated with our US based partner Pacific Biomarkers to produce a cost effective, high-throughput, and highly reproducible efflux assay that was subsequently GLP validated and used for assaying samples from a few global clinical trials. This cholesterol efflux assay is now available for regulated bioanalysis of study samples from early to late phase drug-development clinical trials for drugs affecting the lipoprotein metabolism" she added.

About Clinigene International Limited  

Clinigene is India's leading clinical research organization that provides trial management, Clinical & Bioanalytical Lab services and Data Management services for Phase 1-4 clinical trials (Know more - http://www.clinigeneintl.com )

About Pacific Biomarkers (PBI)  

Established in 1989, PBI provides biomarker laboratory services and contract research services to support pharmaceutical and diagnostic manufacturers conducting human clinical trial research (Know more - http://www.pacbio.com)

Contact
Neeraj Upadhyay
Clinigene International Ltd.
Tel: +91-80-2808-2759
Email: neeraj.upadhyay@clinigeneintl.com

©2012 PR Newswire. All Rights Reserved.

Powered by WorldNow

805 Brady Street, Davenport, IA 52803

Telephone: 563.383.7000
Fax: 563.383.7131
Email: news@kwqc.com

Can’t find something?
Powered by WorldNow
All content © Copyright 2000 - 2014 Young Broadcasting of Davenport, Inc. A Media General Company.